<DOC>
	<DOC>NCT01225861</DOC>
	<brief_summary>The primary objective of the study is the descriptive analysis of incidence &amp; severity of side effects &amp; reasons for discontinuation of the treatment of chronic pain with transdermal analgesic Buprenorphine patches.</brief_summary>
	<brief_title>Prospective Study on the Use of Transdermal Analgesic Buprenorphine Patches for Chronic Pain in the UK</brief_title>
	<detailed_description>750 patients that are treated with transdermal Buprenorphine patches for chronic pain will be included in the study. About 20% of patients are aimed to be patch-naive, ie have received their first prescription of transdermal analgesic patches within 1 month before inclusion in this observational study. Furthermore the study should not include more than 25% of cancer patients that are treated for chronic pain in order to ensure an appropriate mix of patient population.</detailed_description>
	<mesh_term>Chronic Pain</mesh_term>
	<criteria>Inclusion Criteria Patient age &gt; 18 Patient is treated with transdermal Buprenorphine The patient is able to answer the patient's survey &amp; has an estimated overall survival of minimum 6 months The patient gives his/her informed, written consent to participate in the study Exclusion Criteria Patient Age &lt; 18 Patient has less than 6 months survival expectancy Patient is unable to answer the patient survey for whatever reason in any feasible form</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
</DOC>